Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Esophageal Neoplasms
  • Matrix Metalloproteinase Inhibitors
  • Organic Chemicals
  • Protease Inhibitors

abstract

  • All patients, regardless of treatment arm, were able to successfully undergo neoadjuvant combined modality therapy and esophagectomy. However, early closure of the study due to unexpected thrombo-embolic events precluded any conclusions regarding clinical activity of prinomastat in locally advanced esophageal cancer patients.

publication date

  • March 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1007/s10637-006-5934-5

PubMed ID

  • 16502351

Additional Document Info

start page

  • 135

end page

  • 40

volume

  • 24

number

  • 2